Sailaja Puttagunta

2.5k total citations
45 papers, 1.6k citations indexed

About

Sailaja Puttagunta is a scholar working on Pharmacology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Sailaja Puttagunta has authored 45 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pharmacology, 17 papers in Infectious Diseases and 15 papers in Epidemiology. Recurrent topics in Sailaja Puttagunta's work include Antibiotics Pharmacokinetics and Efficacy (20 papers), Antimicrobial Resistance in Staphylococcus (17 papers) and Bacterial Identification and Susceptibility Testing (12 papers). Sailaja Puttagunta is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (20 papers), Antimicrobial Resistance in Staphylococcus (17 papers) and Bacterial Identification and Susceptibility Testing (12 papers). Sailaja Puttagunta collaborates with scholars based in United States, United Kingdom and Latvia. Sailaja Puttagunta's co-authors include Michael W. Dunne, Helen W. Boucher, George H. Talbot, Anita Das, James Baldassarre, Mark Wilcox, Michael T. Zelasky, Scott Van Wart, Philip Giordano and Chris Rubino and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and SHILAP Revista de lepidopterología.

In The Last Decade

Sailaja Puttagunta

45 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sailaja Puttagunta United States	21	945	505	458	347	324	45	1.6k
Katie E. Barber United States	21	827 0.9×	421 0.8×	405 0.9×	176 0.5×	471 1.5×	89	1.5k
Cheng‐Mao Ho Taiwan	22	412 0.4×	210 0.4×	91 0.2×	268 0.8×	445 1.4×	43	1.2k
Jennifer S. McDanel United States	13	667 0.7×	337 0.7×	175 0.4×	117 0.3×	357 1.1×	25	1.1k
Jin‐Yong Jeong South Korea	24	447 0.5×	222 0.4×	148 0.3×	124 0.4×	529 1.6×	47	1.4k
Efthymia Protonotariou Greece	19	247 0.3×	227 0.4×	265 0.6×	171 0.5×	348 1.1×	82	1.5k
G J Cuchural United States	18	298 0.3×	708 1.4×	302 0.7×	248 0.7×	259 0.8×	27	1.3k
Elizabeth Palavecino United States	22	529 0.6×	312 0.6×	64 0.1×	169 0.5×	472 1.5×	89	1.4k
Grace C. Lee United States	17	339 0.4×	167 0.3×	152 0.3×	109 0.3×	328 1.0×	41	1.1k
Alessia Carnelutti Italy	16	288 0.3×	186 0.4×	125 0.3×	110 0.3×	325 1.0×	42	833
Vered Schechner Israel	15	411 0.4×	218 0.4×	167 0.4×	64 0.2×	534 1.6×	47	1.3k

Countries citing papers authored by Sailaja Puttagunta

Since Specialization

Citations

This map shows the geographic impact of Sailaja Puttagunta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sailaja Puttagunta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sailaja Puttagunta more than expected).

Fields of papers citing papers by Sailaja Puttagunta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sailaja Puttagunta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sailaja Puttagunta. The network helps show where Sailaja Puttagunta may publish in the future.

Co-authorship network of co-authors of Sailaja Puttagunta

This figure shows the co-authorship network connecting the top 25 collaborators of Sailaja Puttagunta. A scholar is included among the top collaborators of Sailaja Puttagunta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sailaja Puttagunta. Sailaja Puttagunta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Maher, Joshua, Michael D. Huband, Paul R. Rhomberg, et al.. (2025). Characterization of sulopenem antimicrobial activity using in vitro time-kill kinetics, synergy, post-antibiotic effect, and sub-inhibitory MIC effect methods against Escherichia coli and Klebsiella pneumoniae isolates. Microbiology Spectrum. 13(3). e0189824–e0189824. 1 indexed citations

Dunne, Michael W., Steven I. Aronin, Anita Das, et al.. (2024). A phase 3 randomized trial of sulopenem vs. ertapenem in patients with complicated intra-abdominal infections. Clinical Microbiology and Infection. 31(3). 396–401. 6 indexed citations

VanScoy, Brian, Catherine E. Vincent, Sujata M. Bhavnani, et al.. (2023). 2568. Characterization of Sulopenem Pharmacokinetics-Pharmacodynamics Using a One-Compartment In Vitro Infection Model. Open Forum Infectious Diseases. 10(Supplement_2). 3 indexed citations

Maher, Joshua, et al.. (2023). In vitro activity of sulopenem and comparator agents against Enterobacterales and anaerobic clinical isolates collected during the SENTRY Antimicrobial Surveillance Program. Journal of Antimicrobial Chemotherapy. 78(6). 1406–1414. 7 indexed citations

VanScoy, Brian, Catherine E. Vincent, Sujata M. Bhavnani, et al.. (2023). 2569. Pharmacokinetic-Pharmacodynamic Evaluation of Sulopenem Using a Five-Day Hollow-Fiber In Vitro Infection Model. Open Forum Infectious Diseases. 10(Supplement_2). 2 indexed citations

Dunne, Michael W., Sailaja Puttagunta, Steven I. Aronin, et al.. (2022). Impact of Empirical Antibiotic Therapy on Outcomes of Outpatient Urinary Tract Infection Due to Nonsusceptible Enterobacterales. Microbiology Spectrum. 10(1). e0235921–e0235921. 26 indexed citations

González, Pedro, Urania Rappo, Veronica Mas Casullo, et al.. (2021). Safety of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Nephrotoxicity Rates Compared with Vancomycin: A Post Hoc Analysis of Three Clinical Trials. Infectious Diseases and Therapy. 10(1). 471–481. 7 indexed citations

González, Pedro, et al.. (2021). Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials. Infectious Diseases and Therapy. 11(1). 423–434. 6 indexed citations

Rappo, Urania, Pedro González, Sailaja Puttagunta, et al.. (2019). Single-dose dalbavancin and patient satisfaction in an outpatient setting in the treatment of acute bacterial skin and skin structure infections. Journal of Global Antimicrobial Resistance. 17. 60–65. 31 indexed citations

10.

González, Pedro, et al.. (2018). Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs. Drugs in Context. 7. 1–10. 20 indexed citations

11.

Dunne, Michael W., et al.. (2018). 1393. A Phase 1, Randomized, Open-Label, Crossover Study in Healthy Subjects Under Fasting Conditions of Orally Administered Sulopenem Etzadroxil Alone or with Probenecid to Determine the Pharmacokinetics of Sulopenem. Open Forum Infectious Diseases. 5(suppl_1). S428–S429. 1 indexed citations

12.

González, Daniel, John S. Bradley, Jeffrey L. Blumer, et al.. (2016). Dalbavancin Pharmacokinetics and Safety in Children 3 Months to 11 Years of Age. Open Forum Infectious Diseases. 3(suppl_1). 6 indexed citations

13.

Owens, Robert C., et al.. (2015). Pharmacokinetics, Safety, and Tolerability of a Single 500-mg or 1000-mg Intravenous Dose of Dalbavancin in Healthy Japanese Subjects. Clinical Drug Investigation. 35(12). 785–793. 15 indexed citations

14.

Dunne, Michael W., George H. Talbot, Helen W. Boucher, Mark H. Wilcox, & Sailaja Puttagunta. (2015). Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies. Drug Safety. 39(2). 147–157. 58 indexed citations

15.

Dunne, Michael W., Sailaja Puttagunta, Philip Giordano, et al.. (2015). A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection. Clinical Infectious Diseases. 62(5). 545–551. 173 indexed citations

16.

Boucher, Helen W., Mark Wilcox, George H. Talbot, et al.. (2014). Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection. New England Journal of Medicine. 370(23). 2169–2179. 329 indexed citations

17.

Bradley, John S., Sailaja Puttagunta, Christopher M. Rubino, et al.. (2014). Pharmacokinetics, Safety and Tolerability of Single Dose Dalbavancin in Children 12–17 Years of Age. The Pediatric Infectious Disease Journal. 34(7). 748–752. 40 indexed citations

18.

Quartin, Andrew A., Ernesto G. Scerpella, Sailaja Puttagunta, & Daniel H. Kett. (2013). A comparison of microbiology and demographics among patients with healthcare-associated, hospital-acquired, and ventilator-associated pneumonia: a retrospective analysis of 1184 patients from a large, international study. BMC Infectious Diseases. 13(1). 561–561. 73 indexed citations

19.

Ledizet, Michel, Thomas S. Murray, Sailaja Puttagunta, et al.. (2012). The Ability of Virulence Factor Expression by Pseudomonas aeruginosa to Predict Clinical Disease in Hospitalized Patients. PLoS ONE. 7(11). e49578–e49578. 23 indexed citations

20.

Collins, R, et al.. (1996). Desmosomal Cadherin Binding Domains of Plakoglobin. Journal of Biological Chemistry. 271(18). 10904–10909. 104 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact